Phathom Pharmaceuticals, Inc. $PHAT Holdings Lifted by GW&K Investment Management LLC

GW&K Investment Management LLC increased its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 14.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,306,678 shares of the company’s stock after buying an additional 162,348 shares during the quarter. GW&K Investment Management LLC owned 1.83% of Phathom Pharmaceuticals worth $21,678,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Millennium Management LLC lifted its position in Phathom Pharmaceuticals by 125.8% in the 3rd quarter. Millennium Management LLC now owns 5,081,451 shares of the company’s stock worth $59,809,000 after buying an additional 2,830,954 shares in the last quarter. Moore Capital Management LP purchased a new stake in Phathom Pharmaceuticals in the 2nd quarter worth approximately $5,754,000. Invesco Ltd. lifted its position in Phathom Pharmaceuticals by 13.4% in the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after buying an additional 489,260 shares in the last quarter. Vanguard Group Inc. lifted its position in Phathom Pharmaceuticals by 15.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company’s stock worth $37,847,000 after buying an additional 428,261 shares in the last quarter. Finally, SummitTX Capital L.P. purchased a new stake in Phathom Pharmaceuticals in the 3rd quarter worth approximately $4,543,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Stock Performance

NASDAQ PHAT opened at $9.82 on Thursday. The company has a fifty day simple moving average of $11.55 and a 200 day simple moving average of $12.93. The company has a market cap of $783.24 million, a P/E ratio of -4.63 and a beta of 0.50. Phathom Pharmaceuticals, Inc. has a 1 year low of $7.61 and a 1 year high of $18.31.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Barclays upgraded shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $16.00 to $18.00 in a research report on Friday, March 27th. Guggenheim increased their target price on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus set a $28.00 price target on Phathom Pharmaceuticals in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $24.50.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.